Ascend Capital’s Heron Therapeutics HRTX Stock Holding History

Ascend Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-125,663	Closed	-$1.75M	–	192
2014 Q1	$1.75M	Buy	+125,663	New	+$1.68M	0.05%	171

Other funds holding HRTX

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Savitr Capital San Francisco, California $57M AUM 14.52% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ascend Capital's HRTX Position: Q2 2014 in Review

Ascend Capital sold out of Heron Therapeutics (HRTX) in Q2 2014, closing a stake of 125,663 shares — an estimated $1.75M sold.

Ascend Capital first reported a position in HRTX in Q1 2014 and held it in 1 quarter. The position peaked at $1.75M in Q1 2014. 69 funds tracked by Wall St. Rank hold HRTX as of Q2 2014.

Ascend Capital reported no remaining Heron Therapeutics position as of Q2 2014 after selling out during the quarter.
Ascend Capital sold 125,663 Heron Therapeutics shares in Q2 2014, an estimated $1.75M.
Ascend Capital first reported a position in Heron Therapeutics in Q1 2014 and held it in 1 quarter.
Ascend Capital's Heron Therapeutics position peaked at $1.75M in Q1 2014.
69 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2014.

Based on Ascend Capital's 13F filing for Q2 2014, filed 13 Aug 2014.